--- title: "Azitra | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295713923.md" datetime: "2026-08-12T21:44:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295713923.md) - [en](https://longbridge.com/en/news/295713923.md) - [zh-HK](https://longbridge.com/zh-HK/news/295713923.md) generator: "portal-rs" --- # Azitra | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.17. EBIT: As of FY2026 Q2, the actual value is USD -3.346 M, beating the estimate of USD -3.601 M. #### Financial Performance for the Three Months Ended June 30, 2026 - **Research and Development (R&D) Expenses**: R&D expenses for Azitra, Inc. were $1,351,529 for the quarter ended June 30, 2026, a slight decrease compared to $1,401,839 for the comparable period in 2025. - **General and Administrative (G&A) Expenses**: G&A expenses increased to $2,067,639 for the quarter ended June 30, 2026, from $1,469,513 in the comparable period of 2025. - **Total Operating Expenses**: Total operating expenses for the quarter were $3,419,168 in 2026, up from $2,871,352 in 2025. - **Loss from Operations**: The loss from operations was - $3,419,168 for the three months ended June 30, 2026, compared to - $2,871,352 for the same period in 2025. - **Net Loss**: Azitra, Inc. reported a net loss of - $3,347,660 for the quarter ended June 30, 2026, an increase from - $2,888,993 for the comparable period in 2025. - **Net Loss per Share**: Basic and diluted net loss per share was - $0.17 for the quarter ended June 30, 2026, compared to - $1.18 for the same period in 2025. #### Financial Position as of June 30, 2026 - **Cash and Cash Equivalents**: As of June 30, 2026, Azitra, Inc. had cash and cash equivalents of $6,727,810, significantly up from $2,068,083 as of December 31, 2025. - **Total Current Assets**: Total current assets amounted to $7,443,822 as of June 30, 2026, compared to $3,019,327 as of December 31, 2025. - **Total Assets**: Total assets were $8,916,046 as of June 30, 2026, an increase from $5,025,386 as of December 31, 2025. - **Total Current Liabilities**: Total current liabilities were $1,530,709 as of June 30, 2026, up from $1,067,966 as of December 31, 2025. - **Total Liabilities**: Total liabilities reached $1,581,707 as of June 30, 2026, compared to $1,224,156 as of December 31, 2025. - **Total Stockholders’ Equity**: Total stockholders’ equity increased to $7,334,339 as of June 30, 2026, from $3,801,230 as of December 31, 2025. #### Operational Metrics and Business Highlights (Q2 2026) - Azitra, Inc. reported the first preclinical data from ATR-COSF, demonstrating breakthrough repeat-dose distribution, controlled delivery into targeted skin layers, and anti-wrinkle activity in ex vivo human skin. - The company continued enrollment for the first cohort in the Phase 1⁄2 clinical trial evaluating ATR-04 for EGFR inhibitor-associated rash. - Recombinant protein initiatives, including Tobacco Etch Virus (TEV) Protease and T7 RNA Polymerase, were advanced, expanding the company’s platform into biotechnology research and manufacturing applications. - Azitra, Inc. issued a CEO Letter to Shareholders detailing an expanded strategy to leverage its microbial genetic engineering platform across therapeutics, cosmetic ingredients, and biotechnology products. - The company plans to strategically pause further enrollment in the ongoing Phase 1b study evaluating ATR-12 for Netherton syndrome, reflecting a disciplined approach to capital allocation. #### Outlook and Upcoming Milestones Azitra, Inc. plans to advance ATR-COSF toward a planned proof-of-concept clinical study, with a human cosmetic application study expected to start in Q3 2026. The company anticipates reporting topline data from the first cohort of the Phase 1⁄2 trial for ATR-04 around year-end 2026. Additionally, Azitra, Inc. will continue developing its recombinant protein portfolio to broaden its long-term commercial potential. ### Related Stocks - [AZTR.US](https://longbridge.com/en/quote/AZTR.US.md) ## Related News & Research - [Azitra COO Travis Whitfill presents at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/298315399.md) - [Essex Property Trust declares Q3 2026 dividend of R$ 0.89 per unit](https://longbridge.com/en/news/298322539.md) - [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md) - [Sanlorenzo announces publication of half-year financial report as of June 30, 2026](https://longbridge.com/en/news/298226515.md) - [HF Sinclair announces Q3 2026 dividend of R$ 1.81 per unit](https://longbridge.com/en/news/298317474.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**